文献速递炎症性肠病

抗TNFα治疗对3001例儿童及青少年溃疡性结肠炎患者结肠切除率和皮质类固醇使用的影响:1995-2015年全国性研究

The impact of anti-TNFα therapy on colectomy rates and corticosteroid treatment among 3001 paediatric and adolescent patients with ulcerative colitis-a nationwide study from 1995 to 2015.
PubMed 文献 · Aliment Pharmacol Ther · 2019-10-03

这项丹麦全国性队列研究纳入1995-2015年诊断的0-20岁溃疡性结肠炎患者3001例,比较抗TNFα时代(2004-2015)与历史队列(1995-2003)的5年结肠切除累积风险。抗TNFα时代5年结肠切除比例为9.7%,历史队列为12.3%,调整后HR为0.76(95%CI 0.60-0.96)。334例接受抗TNFα治疗的患者中,后续3个月内16.8%使用皮质类固醇,6个月和12个月时分别降至5.4%和1.2%。

要点

  • 抗TNFα时代儿童及青少年UC患者5年结肠切除风险较历史队列降低(HR 0.76)。
  • 抗TNFα治疗后3个月内皮质类固醇使用率为16.8%,12个月时降至1.2%。

核心结论

  • 在≤20岁溃疡性结肠炎患者中,抗TNFα时代诊断后5年内结肠切除的风险比历史队列降低。
  • 接受抗TNFα治疗的患者,12个月后皮质类固醇处方几乎停止。

研究设计与样本

  • 丹麦全国性队列研究,基于 Danish health registries 纳入1995-2015年诊断的0-20岁溃疡性结肠炎患者3001例。
  • 比较历史队列1(1995-2003,抗TNFα前时代)与队列2(2004-2015,抗TNFα时代)。
  • 抗TNFα使用者定义为4个月内至少接受4次抗TNFα治疗。

主要发现

  • 队列2的5年结肠切除累积比例为9.7%(95%CI 8.4-11.1),队列1为12.3%(95%CI 10.4-14.6)。
  • 队列2相比队列1的调整5年结肠切除风险比(HR)为0.76(95%CI 0.60-0.96)。
  • 334例接受抗TNFα治疗的患者中,16.8%(56/334)在后续3个月内被处方皮质类固醇。
  • 皮质类固醇使用随随访下降,6个月和12个月时分别为5.4%和1.2%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The long-term effects of anti-TNFα therapy in ulcerative colitis are debatable. AIM: To examine whether anti-TNFα therapy changed the colectomy proportion and reduced the use of corticosteroids. METHODS: A nationwide cohort study among patients (age 0-20) diagnosed with ulcerative colitis through 1995-2015 from Danish health registries. We calculated the cumulative 5-year risk of colectomy after diagnosis and used a Cox regression model for comparison between a historical pre-anti-TNFα cohort 1 (1995-2003) and a cohort 2 for the era of anti-TNFα (2004-2015). Based on anti-TNFα users, defined as patients who had at least four anti-TNFα treatments within 4 months, we examined the subsequent need for corticosteroids. RESULTS: We identified 3001 patients from 1995 to 2015. The 5-year cumulative proportion of colectomy in cohort 2 was 9.7% (95% confidence interval [CI] 8.4-11.1) and 12.3% (95% CI 10.4-14.6) in cohort 1. The adjusted 5-year hazard ratio (HR) was 0.76 (95% CI 0.60-0.96) for colectomy in cohort 2 compared to cohort 1. A total of 334 patients received anti-TNFα treatments, and 16.8% (56/334) were prescribed corticosteroids in the subsequent 3-month period. Corticosteroid treatment declined with follow-up after 6 and 12 months, 5.4% and 1.2%, respectively. CONCLUSION: In patient's ≤20 years, the HR for colectomy within a period of 5 years from the time of diagnosis was reduced in the era of anti-TNFα compared to a historical cohort. In patients treated with anti-TNFα, prescriptions of corticosteroids were virtually ceased after 12 months.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Lund K, Larsen MD, Knudsen T, et al. The impact of anti-TNFα therapy on colectomy rates and corticosteroid treatment among 3001 paediatric and adolescent patients with ulcerative colitis-a nationwide study from 1995 to 2015. Aliment Pharmacol Ther. 2019. PMID: 31579961. doi:10.1111/apt.15510

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。